AstraZeneca to buy in vivo cell therapy company, EsoBiotec for US$ 1billion: Cambridge, UK Tuesday, March 18, 2025, 10:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceu ...
Zacks Investment Research on MSN12d
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell TherapiesAstraZeneca AZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell ...
EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...
AstraZeneca announced on Monday that it is spending up to $1bn to acquire Belgian biotech firm EsoBiotec, which it says has ...
AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1bn, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, and ...
AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...
Cambridge: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback